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Current interventions for the treatment of acute kidney injury
(AKI) are not satisfactory, and it is time to approach new
strategies in order to definitely take a step forward. At its
beginning, cell therapy was innovative and promising.
We have shown that mesenchymal stem cells (MSCs), isolated
from human and murine bone marrow (BM), behave as
an efficacious tool for the treatment of cisplatin-induced
AKI in mice in terms of amelioration of renal function and
structure, and animal survival. Although the mechanism
has not been completely elucidated, we have provided data
showing that BM-MSC-mediated renal recovery involves the
release at the site of injury of the growth factor, insulin-like
growth factor-1. Several biological effects have been
observed in renal tissues of mice treated with BM-MSCs,
including increased cell proliferation, hemodynamic changes,
and cell apoptosis reduction. In the same experimental
model, we have tested the effect of MSCs isolated from
cord blood (CB-MSCs), which, similar to BM-MSCs, not only
ameliorated renal function but also protected animals from
death to a remarkably higher extent. Animals receiving
CB-MSCs showed reduction of oxidative stress and activation
of AKT prosurvival pathway in tubular cells. These results
hold great promise for future studies in patients with AKI.
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The increased interest toward mesenchymal stem cells
(MSCs) is associated with the prominent role that these cells
have recently provoked in tissue regeneration. Mainly, they
represent an important component of the hematopoietic stem
cell niche in the bone marrow (BM), where they contribute to
hematopoietic stem cell maturation.1,2 In kidney regenera-
tion, in which the quest for a pharmacological therapy in
acute kidney injury (AKI) has been largely unsuccessful,
BM-MSCs might represent a valid therapeutic tool.
Acknowledged evidence has proved that BM supplies
kidney with cells for physiological turnover or regeneration
of tubular epithelial cells.3 Our group investigated the use of
BM-MSCs as cell therapy for AKI and documented for the
first time that murine BM-MSCs contributed to renal repair
and recovery from AKI.4 By means of intravenous injection,
murine BM-MSCs ameliorated renal function and tubular
injury of mice with AKI induced by the nephrotoxic
anticancer agent cisplatin (Table 1).4,5 In the same experi-
mental model, hematopoietic stem cells had no protective
effect.4 Therefore, it is important to understand which BM-
MSCs properties make these cells responsible for their
decisive role in kidney repair. In kidneys of AKI-injured
mice supplied with BM-MSCs, we observed, by Ki67 staining,
a marked increase of tubular cell proliferation, a fundamental
step by which kidney restores normal architecture after acute
damage. Proliferating cells were identified as endogenous
renal cells, as the vast majority of the cells lacked Y chromo-
some, the marker used for identifying BM-MSC male
cells given to female mice, and were negative for PKH-26,
the cell tracker used to stain BM-MSCs before their
administration.4,5
However, the mechanism responsible for the repair was
still unclear. Indeed, in the face of a remarkable renoprotec-
tive and regenerative effect, in the kidney, the number of
BM-MSCs was quantitatively very low, with an engraftment
of PKH-26 MSC in the renal tissue that averaged 1.1±0.7
BM-MSC/105 renal cells.5 Moreover, the occasional differ-
entiation of these cells into tubular cells could not explain
and sustain per se such a therapeutic effect.
Two considerations have been useful to advance a working
hypothesis on the mechanism for regeneration of tubular
epithelium: the first is that growth factors have the leading
role in induction of a proliferative repair,6,7 and the second is
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that BM-MSCs are responsible for the secretion of multiple
bioactive factors.8–11 Particularly, in the kidney, studies on
rats with ischemia/reperfusion injury have indicated that
BM-MSCs-mediated renal repair was associated with a high
renal production of growth factors such as hepatocyte growth
factor, vascular growth factor, and insulin-like growth
factor-1 (IGF-1).8 Moreover, the effect of BM-MSCs was
accompanied by the tissue downregulation of proinflamma-
tory cytokines and upregulation of prosurvival mediators.8
These reasons prompted us to hypothesize that MSCs afford
protection primarily through a paracrine pathway, and to
investigate, among potential candidates, the contribution of
IGF-1 to tissue protection. IGF-1 is constitutively expressed
and secreted by BM-MSCs,8,12 possesses mitogenic and anti-
apoptotic properties,13,14 and is implicated as an important
mediator in kidney regeneration in models of AKI.13,15,16
Our studies showed that in vitro, murine BM-MSCs induce
proliferation of cisplatin-damaged tubular cells and protect
tubular cells from cisplatin-induced apoptosis via IGF-1.5
Direct blocking of IGF-1, by specific IGF-1 small interfering
RNAs or by specific antibody, confirmed that BM-MSC-
derived IGF-1 mediated the proliferation of cisplatin-
damaged tubular cells (Figure 1). Although partially, the
inhibition of cisplatin-induced apoptosis on proximal
tubular cells was also found to be IGF-1 mediated (Figure 1).
In vivo, we have found confirmation of this evidence.
Administration of IGF-1 gene-silenced BM-MSCs failed to
protect renal function and tubular structure of mice injured
with cisplatin. When BM-MSC localization within the
kidney was explored, these cells were preferentially found
in peritubular areas, further supporting the notion that their
mitogenic and antiapoptotic action was exerted through
a paracrine mechanism. These findings have opened up new
extensive investigations on the effects of BM-MSCs princi-
pally in the surroundings of the tubuli. In the future perspec-
tive to use BM-MSCs in clinic, we used MSCs obtained from
human BM aspirates to treat cisplatin-injured immunodefi-
cient nonobese diabetes/severe combined immunodeficiency
mice.17 Similar to the corresponding murine cells, human
BM-MSCs were engaged to engraft the kidney and to
preserve its tubular integrity and renal function, ultimately
leading to a proliferation and reduced apoptosis of tubular
cells. Moreover, we reported a clear effect on survival of mice
receiving human BM-MSCs as compared with AKI mice that
were administered saline.17 It is fully recognized that the
main target of cisplatin-induced damage is tubular epithelial
cell with DNA damage, mitochondrial dysfunction, and
reactive oxygen species production, followed by apoptosis.
However, cisplatin also induces intrarenal vasoactive media-
tors18 and proinflammatory factors, specifically tumor
necrosis factor-a, which perturbs the peritubular endothe-
lium19 leading to inflammatory cell migration and leukocyte-
mediated changes of vascular tone and perfusion. The
persistent vasoconstriction and reduction of blood flow,
which develop later than the tubular epithelial damage, have
been suggested to amplify the deleterious effects of tubular
cell injury in AKI.20 These observations were confirmed in
our AKI experimental model, where peritubular capillaries
were significantly reduced in volume density and diameter.
Notably, human BM-MSCs treatment not only protected
against tubular cell damage but also almost completely
normalized the endothelium and lumen density, as well as the
capillary diameters (Figure 2).17 These findings add new
intriguing information about the role of MSCs in kidney
Table 1 | Bone marrow-derived mesenchymal stem cells
(BM-MSCs) protected cisplatin-treated mice from renal
function deterioration and renal histology changes
Control
Cisplatin+saline
(4d)
Cisplatin+BM-
MSCs (4d)
Renal function
BUN (mg/dl) 17.02±1.00 82.54±5.12* 33.43±3.0611
Renal histology
Casts 0 1.77±0.20 0.50±0.1911
Tubular cell
degeneration
0 1.54±0.14 0.62±0.181
Cell loss 0 1.38±0.18 0.12±0.1211
Mice were subcutaneously administered with cisplatin (12.7mg/kg) and 24 h later
BM-MSCs (2 105 cells) were given intravenously in the tail vein. Animals were killed
at day 4 (4d). Renal function was measured as blood urea nitrogen (BUN). Renal
histology was evaluated as periodic acid Shiff-positive droplets, cell debris in tubular
lumens, and tubular degeneration consisting of brush border loss, nuclear changes,
and vacuolization. BUN and histology data are mean values±s.e.m. and mean
score±s.e.m., respectively. *Po0.01 versus control; 1Po0.05, 11Po0.01 versus
cisplatin+saline.
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Figure 1 |Bone marrow-mesenchymal stem cells (BM-MSCs)
stimulated proximal tubular cell (PTEC) proliferation and
inhibited cisplatin-induced apoptosis via insulin-like growth
factor-1 (IGF-1). (a) Proliferation of PTECs treated with cisplatin
(2.5mM, 6 h), alone or in coculture for 4 days with BM-MSCs
transfected with irrelevant (irrel) or IGF-1 small interfering (si)
RNAs. Blocking of IGF-1 by RNA silencing (si-IGF-1) led to a strong
reduction in the proliferation of cisplatin-treated PTECs as
compared with BM-MSCs transfected with si-irrel. 1Po0.01 versus
PTECs; *Po0.01 versus PTECsþ cisplatin; #Po0.05 versus si-irrel
BM-MSCs. Data are means±s.e.m. (b) Cisplatin-induced apoptosis
on PTECs is reduced by BM-MSCs treatment via IGF-1. Untreated
PTECs and cisplatin-treated PTECs, alone or in coculture for 4 days
with si-irrel BM-MSCs or si-IGF-1 BM-MSCs, were analyzed by
fluorescence-activated cell sorter to determine late apoptosis
(expression of caspase 3 and 7, propidium iodide). 1Po0.01 versus
PTECs; *Po0.01 versus PTECsþ cisplatin; #Po0.05 versus si-irrel
BM-MSCs and PTECsþ cisplatin. Data are means±s.e.m.
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recovery from AKI. Amelioration of hemodynamic changes,
likely consequence of a more pervious capillary, should yield
advantageous effects increasing tissue oxygenation, reducing
endothelial cell activation, and preserving microvascular
integrity. Finally, an active role of BM-MSCs on endothelial
cells cannot be excluded considering that these cells might
induce prosurvival pathways and antioxidant mechanisms.
However, several of these pathways still need to find experi-
mental confirmation. At the moment, the overall findings can
only suggest a hypothesis for the complex link of BM-
MSCs-mediated regeneration. Following MSC recruitment
to damaged tissues, the recovery process starts and passes
Control Cisplatin + saline Cisplatin + hBM-MSCs
Figure 2 | Effect of human bone marrow-mesenchymal stem cells (hBM-MSCs) on peritubular capillaries in immunodeficient mice
with cisplatin-induced acute kidney injury. Representative micrografts of kidney tissues of control mouse and cisplatin-treated mice that
were administered saline or hBM-MSCs at 4 days after cisplatin. The peritubular capillary endothelium was labeled with MECA-32 (red),
whereas renal structures were stained with fluorescein isothiocyanate-labeled lectin wheat germ agglutinin (green). Volume density of
endothelial cells and capillary lumen was markedly reduced in cisplatin-treated mice that were administered saline as compared with
control mice, as well as their capillary diameter. Treatment with hBM-MSCs normalized all these parameters. Original magnification,  630.
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Figure 3 | Suggested mechanism for mesenchymal stem cell (MSC)-mediated tubular repair after acute injury. Administered MSCs
are attracted to the site of injury following cytokine and chemokine release from damaged tubular cells. Recruited MSCs release
growth factors such as insulin-like growth factor-1 (IGF-1), which may affect tubular functional and structural repair by induction of
cell proliferation and inhibition of apoptosis. MAP-kinase, mitogen-activated protein kinase; PI3K, phosphatidylinositol 3-kinase.
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through MSC-secreted growth factors, one of which is
certainly IGF-1, which promotes prosurvival pathways and
stimulates tubular cell proliferation (Figure 3).
Studies conducted by our group on MSCs obtained from a
different source, the human cord blood (CB-MSCs), con-
firmed and extended some of the findings highlighted
for BM-MSCs.21 Specifically, data in murine model of
cisplatin-induced AKI showed the great potential of
CB-MSC in terms of protection from renal function
impairment and remarkable prolongation of animal survival.
CB-MSC treatment led to reduction of apoptosis and tubular
cell proliferation. Moreover, the favorable effect on renal
tissues was associated with inhibition of tubular oxida-
tive damage, in terms of nitrotyrosine expression and
induction of the phosphorylation of the prosurvival factor
Akt.21 Similar to the MSCs derived from BM, CB-MSCs
almost exclusively localized in the peritubular areas where
they are likely to promote regeneration through paracrine
action. In support to this statement are in vitro experiments
showing that the proregenerative growth factors fibroblast
growth factor, heparin binding-epidermal growth factor-like
growth factor, vascular endothelial growth factor, and
hepatocyte growth factor are increased in the supernatant
of cisplatin-treated proximal tubular cells cocultured with
CB-MSCs. The release of inflammatory cytokines, such as
interleukin-1a and transforming growth factor-b, was found
to be decreased.21
Studies that aimed to further clarify the mecha-
nism responsible for renoprotection by MSCs obtained
from different sources are now essential to support an
educated answer to the question of which cell type will
definitely represent the best therapeutic strategy for kidney
regeneration.
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